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1  | INTRODUC TION
Osteoarthritis (OA) is the main cause of incapacity in elderly pop‐
ulation, although other factors such as obesity, metabolism and 
previous joint damage also generate patients’ disability. OA is char‐
acterized by loss of cartilage extracellular matrix (ECM) homeostasis, 
leading to its destruction. Despite cartilage degradation is the most 
remarkable symptom of OA, other tissues of the joint are also af‐
fected, including subchondral bone, tendons, ligaments as well as 
the synovial membrane. Matrix‐degrading enzymes released by 
chondrocytes and synovial fibroblasts (SF) induce cartilage matrix 
degradation in OA.1 It is well known the role of zinc‐dependent 
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Abstract
Failure of therapeutic approaches for the treatment of osteoarthritis (OA) based on 
the inhibition of metalloproteinases, might be because of their constitutive expres‐
sion in homeostasis, together with their network complexity. The knowledge of this 
network would contribute to selective target pathological conditions. In this sense, 
blockade of mediators produced by neighbouring joint cells, such as synovial fibro‐
blasts (SF), would prevent cartilage damage. Thus, we studied the contribution of 
ADAMTS‐7 and ‐12 from SF to cartilage oligomeric matrix protein (COMP) degrada‐
tion, and the signalling pathways involved in their expression. We report for the first 
time in SF, the involvement of ERK‐Runx2 axis and Wnt/β‐catenin signalling in 
ADAMTS‐12 and ADAMTS‐7 expressions, respectively, with the subsequent conse‐
quences in COMP degradation from cartilage extracellular matrix. After stimulation 
with IL‐1β or fibronectin fragments, we showed that ERK inhibition decreased Runx2 
activation and ADAMTS‐12 expression in OA‐SF, also reducing Fn‐fs‐induced COMP 
degradation. Blockage of Wnt signalling by DKK1 reduced ADAMTS‐7 and COMP 
degradation in OA‐SF as well. In addition, Wnt7B expression was induced by IL‐1β 
and by itself, also increasing ADAMTS‐7. Our results could contribute to the develop‐
ment of disease‐modifying OA drugs targeting ADAMTS‐7 and ‐12 for the prevention 
of extracellular matrix components degradation like COMP.
K E Y W O R D S
ADAMTS‐12, ADAMTS‐7, COMP, extracellular matrix, osteoarthritis, Runx2, synovial 
fibroblasts, Wnt signalling
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proteases in the osteoarthritic degradation of the ECM, including 
matrix metalloproteinases (MMPs) and several ADAMTS (a disinteg‐
rin and metalloproteinase with thrombospondin motifs), such as the 
aggrecanases ADAMTS‐4 and ‐5.2,3 Given the limited regeneration 
capacity of the articular cartilage, prevention of its damage, results 
crucial to reduce disease severity. In this sense, the control of inflam‐
mation and proliferation of the synovial membrane in OA patients 
could contribute to cartilage protection.
In rheumatoid arthritis (RA) SF are main players involved in joint 
destruction, but little is known about their contribution to the pa‐
thology of OA. It is known that SF release mediators that contribute 
to joint destruction and to the chronicity of inflammation. Although 
metalloproteinases have been identified as targets of therapeutic in‐
tervention, they probably failed because of their role in homeostasis, 
remodelling and wound healing or might be because of the diver‐
sity of the metalloproteinases network and the complexity of their 
interrelations.4 The knowledge of the location and function of this 
intricate network could contribute to the design of selective targets 
to prevent cartilage destruction.
We have recently reported the involvement of SF in the produc‐
tion of ADAMTS‐4, ‐5, ‐7 and ‐12, and their contribution to ECM 
damage.5 The participation of aggrecanases in cartilage destruction 
is well known, but the specific contribution of ADAMTS‐7 and ‐12 is 
less established. ADAMTS‐7 and ‐12 digest cartilage oligomeric ma‐
trix protein (COMP),6‐8 a non‐collagenous component of cartilage. 
COMP is a protein of the ECM that contributes to the maintenance 
of cartilage stability through its interaction with other components 
such as aggrecan, type II collagen or fibronectin. Moreover, the 
signalling pathways regulating these ADAMTS are poorly under‐
stood. Here we studied whether Runx2 and Wnt/β‐catenin, two 
signalling pathways involved in chondrocytes metabolism and OA 
pathology,9‐11 are implicated in the production of ADAMTS‐7 and 
‐12 in SF. Moreover, we analysed the role of interleukin‐1β (IL‐1β), 
and fibronectin fragments (Fn‐fs), two inflammatory mediators pres‐
ent in OA joints, as inducers of ADAMTS expression.5 Finally, we 
studied the involvement of ADAMTS‐7 and ‐12, and their signalling 
pathways in the regulation of COMP degradation in the cartilage‐SF 
interaction.
2  | MATERIAL S AND METHODS
2.1 | Patients and synovial fibroblasts cultures
Synovial tissue was obtained from eight patients with active OA (five 
women and three men) aged between 65 and 87, at the time of total 
knee joint replacement surgery. Patients had advanced disease and 
were diagnosed of primary OA, excluding trauma, inflammatory dis‐
ease and other structural causes of secondary OA. Control samples 
from healthy donors (HD) were obtained from five patients (three 
women and two men) aged between 50 and 72, at the time of knee 
arthroscopic evaluation. These patients were diagnosed with menis‐
copathy caused by trauma to the knee or sports injury, excluding 
inflammatory and rheumatic diseases. Samples were provided by 
the Rheumatology Service at Complejo Hospitalario Universitario A 
Coruña (CHUAC, A Coruña, Spain). The study was approved by the 
local Ethics Committee (Galicia, Spain) and performed according to 
the recommendations of the Declaration of Helsinki. All biopsy sam‐
ples were obtained after subjects gave informed consent.
SF cultures were established by explant growth of synovial biop‐
sies, cultured in Dulbecco's modified Eagle's medium (DMEM) with 
25 mM HEPES and 4.5 g/L glucose, completed with 10% heat‐in‐
activated foetal bovine serum (FBS) (Lonza Ibérica SAU, Barcelona, 
Spain), 1% l‐glutamine and 1% antibiotic‐antimycotic (Invitrogen, 
Carlsbad, CA), at 37°C and 5% CO2. After three passages, residual 
contamination by macrophages was avoided, previously assessed by 
flow cytometry analysis of SF with a purity of 95%.12 Monocultures 
of SF were used for experiments until passage 6. Despite the use of 
cells at varying passage numbers, all comparisons within the same 
experimentation were made on SF at an identical passage number 
and at 80%‐90% confluent.
2.2 | RNA extraction and RT‐qPCR
Synovial fibroblasts were seeded in 100‐mm petri dishes 
(3 × 105 cells/dish) and cultured in serum‐free DMEM in the presence 
or absence of 10 ng/mL IL‐1β (ImmunoTools, Friesoythe, Germany), 
10 nM 45 kDa Fn‐fs (Sigma‐Aldrich, St Louis, MO) or 100 ng/mL 
Wnt7B (Abnova, Taipei, Taiwan) for 24 hours. For inhibition experi‐
ments, cells were previously cultured in presence of 10 µM mitogen‐
activated protein kinase (MAPK) p38 inhibitor (SB203580), 10 µM 
MAPK Kinase (MEK) and extracellular signal‐regulated kinase (ERK) 
inhibitor (PD98059) (Calbiochem, EMD Biosciences, San Diego, CA) 
or 200 ng/mL Dickkopf‐1 (DKK1) (R&D Systems, Abingdon, OX, 
UK) for 1 hour. Total RNA was obtained using Tri®Reagent (Sigma‐
Aldrich). Two micrograms of RNA were reverse transcribed using a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). Semiquantitative real‐time PCR (qPCR) analysis 
was performed with a TaqMan® Gene Expression Master Mix with 
manufactured‐predesigned primers for ADAMTS‐7, ADAMTS‐12, 
Wnt3A, Wnt7B and β‐actin (Applied Biosystems). Assays were per‐
formed in triplicate. Results were normalized to β‐actin and plotted 
relative to the basal, using the ∆∆ cycle threshold method for quan‐
tification. In some cases, results were normalized to β‐actin and di‐
rectly showed as mRNA expression (×104).
2.3 | Quantification of ADAMTS in culture 
supernatants
SF were seeded in 6‐well plates (6 × 104 cells/well). Cells were cul‐
tured in serum‐free DMEM in the presence or absence of 10 ng/mL 
IL‐1β or 10 nM 45 kDa Fn‐fs for 24 hours. For inhibition experiments, 
cells were previously cultured in the presence of 10 µM SB203580, 
10 µM PD98059 or 200 ng/mL DKK1 for 1 hour. Levels of ADAMTS 
were measured in the cell culture supernatants using commercial 
ELISA kits for ADAMTS‐7 and ADAMTS‐12 (MyBioSource, San 
Diego, CA).
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2.4 | Runx2 assay
Synovial fibroblasts were seeded in 150‐mm petri dishes 
(8 × 105 cells/dish). Cells were cultured in serum‐free DMEM in the 
presence or absence of 10 ng/mL IL‐1β or 10 nM 45 kDa Fn‐fs for 60 
and 30 minutes, respectively. Time‐course of Runx2 activation at 5, 
15 and 30 minutes, and 1 and 2 hours of 10 ng/mL IL‐1β or 10 nM 
45 kDa Fn‐fs treatment was previously performed. For inhibition ex‐
periments, cells were previously cultured in the presence of 10 µM 
SB203580 or PD98059 for 1 hour. A Nuclear Extract Kit (Active 
Motif, Rixensart, Belgium) was used for nuclear extracts prepara‐
tion, and the protein content was measured with a QuantiProTM 
BCA Assay Kit (QBCA) (Sigma‐Aldrich). Nuclear extracts (12 µg/
well) were added to a 96‐well plate and Runx2 activity was measured 
using a TransAMTM AML‐3/Runx2 kit (Active Motif).
2.5 | COMP assay in cartilage‐SF cultures
Release of COMP from OA cartilage was measured in the super‐
natants of SF cultures over cartilage explants.13 OA joint cartilages 
from four patients were provided by the Rheumatology Service at 
Complejo Hospitalario Universitario A Coruña (CHUAC, A Coruña, 
Spain). Fixed diameter (6 mm) sections were collected from adja‐
cent areas to the injured cartilage. Samples were frozen at −80°C 
and stored until testing. One explant per well was attached to a 
96‐well plate. HD‐ or OA‐SF were added drop‐wise on top of the 
cartilage surface (2 × 104 SF per explant). After 3 hours of incuba‐
tion, wells were filled with DMEM in the presence or absence of 
10 µM PD98059 or 200 ng/mL DKK1 for 1 hour, followed by treat‐
ment with 10 ng/mL IL‐1β or 10 nM 45 kDa Fn‐fs. Cultures were 
continued for 7 days, and treatments were renewed every two days. 
Culture supernatants were collected for detection of COMP using a 
Quantikine® Human COMP Immunoassay (R&D Systems).
2.6 | Statistical analysis
Statistical analysis was performed using GraphPad Prism software 
version 6 (GraphPad Inc, San Diego, CA). Data were subjected to 
normality test (Kolmogórov‐Smirnov test) and equal variance test 
(F‐test). Differences were assessed using Student's two‐tailed t 
test for two group comparisons, or one‐way analysis of variance 
(anova) for more than two groups, with a Bonferroni post hoc test 
for comparisons between each two groups. Results are presented 
as mean ± SEM. P‐values <0.05 were considered statistically 
significant.
3  | RESULTS
3.1 | Protein expression of ADAMTS‐7 and ‐12 in 
HD‐ and OA‐SF
To validate at protein level our previous results in ADAMTS‐7 and 
‐12 mRNA transcripts,5 we performed ELISA analysis. Our data in 
culture supernatants confirmed that ADAMTS‐7 release was higher 
in OA than in HD‐SF (Figure 1A), while ADAMTS‐12 levels were simi‐
lar in OA and HD‐SF (Figure 1B).
3.2 | Runx2 and Wnt signalling in ADAMTS‐12 and 
‐7 expressions
Runx2 and Wnt/β‐catenin pathways are involved in the ECM re‐
modelling.14‐16 As we previously reported the implication of the 
proinflammatory mediators IL‐1β and Fn‐fs in ADAMTS‐7 and ‐12 
production,5 we now evaluated the involvement of Runx2 and 
Wnt/β‐catenin signalling in the expression of ADAMTS‐7 and ‐12 
by SF stimulated with these two proinflammatory mediators. To this 
end, we treated the cells with PD98059 or SB203580 as inhibitors of 
ERK and p38 MAPK, respectively, two signalling pathways involved 
in Runx2 activation,17,18 and with DKK1, a well‐known inhibitor of 
the canonical Wnt signalling.19,20
3.2.1 | Runx2 is involved in ADAMTS‐12 expression
Time‐course of Runx2 showed increased activation at 60 and 
30 minutes of 10 ng/mL IL‐1β and 10 nM 45 kDa Fn‐fs treatment, 
respectively (Figure 2A). To validate the participation of ERK and 
p38 MAPK in the induction of Runx2, we measured nuclear activa‐
tion of Runx2 in cells pre‐treated with PD98059 or SB203580 and 
F I G U R E  1   Constitutive protein expression of ADAMTS‐7 and 
‐12 in HD‐ and OA‐SF. Protein secretion of ADAMTS‐7 (A) and 
‐12 (B) was determined by ELISA in culture supernatants (n = 4 
per experimental group). Data are presented as mean ± SEM of 
duplicate determinations. All comparisons with a p‐value less than 
0.05 are shown. *P < 0.05 OA vs HD
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activated with IL‐1β or Fn‐fs at those time points. Our data showed 
that ERK inhibition decreased Runx2 activation in OA‐SF, triggered 
by IL‐1β or Fn‐fs stimulation (Figure 2B). By contrast, we detected 
no differences in cells isolated from HD (Figure S1). No effects were 
observed with the inhibitor of p38. Next, we studied whether ERK 
and p38 MAPK induction of Runx2, or Wnt signalling affected the 
expression and production of ADAMTS‐12. Only ERK inhibition de‐
creased ADAMTS‐12 expression in OA‐SF, after IL‐1β or Fn‐fs stimu‐
lation (Figure 3A). No effects were observed with the inhibitor of 
p38, neither with the inhibitor of Wnt signalling, DKK1 (Figure 3B). 
No differences were observed when cells were obtained from HD 
(Figure S2). Together these data point to the involvement of ERK‐
Runx2 axis in the expression of ADAMTS‐12 in OA‐SF.
3.2.2 | Wnt signalling is implicated in the 
ADAMTS‐7 expression
DKK1 treatment decreased ADAMTS‐7 mRNA as well as protein lev‐
els in OA‐SF (Figure 4B), while only mRNA expression was reduced 
in HD (Figure S3B). We did not observe any effect in cells treated 
with MAPK inhibitors (Figure 4A, Figure S3A). Thus, these results 
suggest the involvement of Wnt/β‐catenin pathway in the expres‐
sion of ADAMTS‐7 induced by IL‐1β or Fn‐fs in SF. We next stud‐
ied whether these two pro‐inflammatory mediators modulated Wnt 
ligands expression. Firstly, we investigated whether SF expressed 
Wnt3A and Wnt7B, two members of the canonical Wnt signalling 
associated with OA physiopathology.21,22 SF did not express Wnt3A 
(data not shown), while Wnt7B mRNA transcripts were detected in 
cells from HD and OA patients with a higher expression in OA‐SF 
(Figure 5A). Moreover, IL‐1β, but not Fn‐fs, induced Wnt7B expres‐
sion (Figure 5B). In addition, Wnt7B also increased its own expres‐
sion (Figure 5B), as well as ADAMTS‐7 mRNA transcripts in OA‐ as 
well as in HD‐SF (Figure 5C).
3.3 | Blockage of COMP releasein cultures of OA‐SF 
over cartilage explants
ADAMTS‐7 and ‐12 share a C‐terminal COMP/GEP‐binding domain, 
which is implicated in the degradation of COMP.7,8 Thus, we stud‐
ied the functional contribution of ADAMTS‐7 and ‐12 produced by 
SF in cartilage damage in OA. SF were cultured over healthy areas 
of cartilage explants from OA patients and COMP degradation was 
assessed in culture supernatants. We first determined the time 
course of COMP release from cartilage explants to the medium in 
the presence of OA‐SF, and observed the highest COMP release on 
day 7 compared to 3 and 5 days (Figure 6A). Cell cultures were also 
performed in presence of DKK1 or PD98059 inhibitors, followed by 
stimulation with IL‐1β or Fn‐fs. In cartilage explants co‐cultured with 
OA‐SF, the inhibition with DKK1 decreased the release of COMP trig‐
gered by both stimuli, while ERK signalling inhibition only decreased 
Fn‐fs‐induced COMP release (Figure 6B,C). Our data indicate that 
under inflammatory conditions (IL‐1β or Fn‐fs), OA‐SF trigger COMP 
degradation mainly via ADAMTS‐7, whereas ADAMTS‐12 is only ac‐
tive in presence of Fn‐fs. DKK1 treatment followed by stimulation 
with Fn‐fs was the only able to decrease COMP in the supernatants 
from cartilage explants cultured with HD‐SF (Figure S4).
4  | DISCUSSION
In an inflammatory context, although OA is primarily characterized 
by chondrocytes degradation, other cells including SF also intervene 
through the activation of different biochemical pathways that trig‐
ger the breakdown of the cartilage ECM mediated by proteinases.5,23 
F I G U R E  2   Activation of Runx2 in OA‐SF. A, Time‐course of 
Runx2 activation after 5, 15 and 30 minutes, and 1 and 2 hours 
of 10 ng/mL IL‐1β or 10 nM 45 kDa Fn‐fs treatment. B, Runx2 
activation was measured in nuclear extracts by TransAM after 
1 hour of treatment with inhibitors PD98059 (iERK) or SB203580 
(ip38), followed by stimulation with IL‐1β for 60 minutes, or 45 kDa 
Fn‐fs for 30 minutes (n = 4 per experimental group). Data are 
presented as the percentage of activation relative to the basal 
(mean ± SEM of duplicate determinations). Dashed horizontal 
line represents the basal value. *P < 0.05, ***P < 0.001 vs IL‐1β, 
#P < 0.05, ##P < 0.01 vs Fn‐fs
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ADAMTS activity is essential in normal ECM remodelling processes. 
However, in OA dysregulation of metalloproteinases contributes to 
disease progression.2,4 The role of collagenases such as MMP‐13, and 
aggrecanases (ADAMTS‐4 and ‐5) has been well documented.2,5,24 
Emergent studies highlight the role of ADAMTS‐7 and ‐12 in inflam‐
matory and rheumatic diseases, including RA and OA, atherosclero‐
sis and cancer.25‐28 However, their function and signalling pathways 
involved in their expression, triggering the damage of non‐col‐
lagenous components of the ECM during OA, have not been well 
established yet. Here we report that protein release of ADAMTS‐7 
in SF from OA patients is higher than in HD, whereas no differences 
were observed in ADAMTS‐12. These data agree with our previous 
findings on their mRNA levels.5
Osteoarthritis is a multifactorial pathology where many inflam‐
matory and degradative mediators play essential roles. In this sense, 
IL‐1β is considered one of the main pleiotropic and proinflammatory 
cytokines in OA.16,29 Besides, cartilage ECM degradation products 
are also relevant in the pathology.30 Amongst them, increased levels 
F I G U R E  3   ADAMTS‐12 expression 
in OA‐SF after inhibition of Runx2 
and Wnt/β‐catenin signalling. SF were 
treated with inhibitors PD98059 (iERK), 
SB203580 (ip38) or DKK1 for 1 hour, 
followed by treatment with IL‐1β or 
45 kDa Fn‐fs for 24 hours (n = 4 per 
experimental group). (A, B) left. mRNA 
expression of ADAMTS‐12 was measured 
by RT‐qPCR. Data are presented as 
mean ± SEM of four independent samples 
analysed in triplicate (see Section 2) 
relative to the basal. (A, B) right. Secretion 
of ADAMTS‐12 was determined by 
ELISA in culture supernatants. Data are 
presented as mean ± SEM of duplicate 
determinations. Dashed horizontal lines 
represent the basal values. *P < 0.05, 
***P < 0.001 vs IL‐1β; #P < 0.05, 
###P < 0.001 vs Fn‐fs
F I G U R E  4   ADAMTS‐7 expression 
in OA‐SF after inhibition of Runx2 
and Wnt/β‐catenin signalling. SF were 
treated with inhibitors PD98059 (iERK), 
SB203580 (ip38) or DKK1 for 1 hour, 
followed by treatment with IL‐1β or 
45 kDa Fn‐fs for 24 hours (n = 4 per 
experimental group). (A, B) left. mRNA 
expression of ADAMTS‐7 was measured 
by RT‐qPCR. Data are presented as 
mean ± SEM of triplicate determinations 
(see Section 2) relative to the basal. 
(A, B) right. Secretion of ADAMTS‐7 
was determined by ELISA in culture 
supernatants. Data are presented as 
mean ± SEM of duplicate determinations. 
Dashed horizontal lines represent the 
basal values. *P < 0.05, **P < 0.01 vs IL‐1β; 
##P < 0.01, ###P < 0.001 vs Fn‐fs
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of fibronectin and its degradative fragments (Fn‐fs) have been de‐
scribed in cartilage and synovial fluid from OA and RA patients, also 
contributing to the degradative and inflammatory process favouring 
the chronicity of the disease.31,32 NF‐kB and AP‐1 have been reported 
as master transcription factors in OA and many other inflammatory 
diseases, also implicated in the transcription of ADAMTS‐7.28,33 
However, little is known about other signalling pathways modulat‐
ing the expression of ADAMTS‐7 and ‐12. Runx2 transcription fac‐
tor and Wnt/β‐catenin signalling are involved in metalloproteinases 
gene expression and OA pathology, promoting the activation of cat‐
abolic mediators.14‐16,34,35 We have previously described their role in 
the expression of ADAMTS‐4 and ‐5.5 Nonetheless, their association 
F I G U R E  5   Expression of Wnt7B in HD‐ and OA‐SF. (A, B) mRNA 
expression of Wnt7B was measured by RT‐qPCR in HD‐ and OA‐SF 
(HD, n = 5 per experimental group; OA, n = 7 per experimental 
group). A, Constitutive mRNA expression of Wnt7B. B, mRNA 
expression of Wnt7B after treatment with IL‐1β, 45 kDa Fn‐fs 
or Wnt7B for 24 hours. C, mRNA expression of ADAMTS‐7 was 
measured by RT‐qPCR in HD‐ and OA‐SF after treatment with 
Wnt7B for 24 hours (n = 4 per experimental group). &P < 0.05 OA 
vs HD; *P < 0.05, ***P < 0.001 vs Basal. Values are presented as 
mean ± SEM of triplicate determinations (see Section 2) F I G U R E  6   Blockage of COMP release in cultures of OA‐SF over 
cartilage explants. OA‐SF were seeded over cartilage explants and 
treated with IL‐1β or Fn‐fs for 7 days, with or without previous 
inhibition with DKK1 or PD98059 (iERK). COMP was detected by a 
Quantikine® Human COMP Immunoassay in culture supernatants 
(n = 4 per experimental group). A, Time‐course of COMP at 3, 5 and 
7 days at basal conditions. Data are presented as the percentage 
of 3 days (mean ± SEM of quadruplicate determinations). B, 
COMP concentration at day 7 of IL‐1β‐stimulation with DKK1 
or iERK. Data are presented as the percentage relative to IL‐1β‐
stimulation (mean ± SEM of quadruplicate determinations). C, 
COMP concentration at day 7 of 45 kDa Fn‐fs‐stimulation with 
DKK1 or iERK. Data are presented as the percentage relative to 
Fn‐fs‐stimulation (mean ± SEM of quadruplicate determinations). 
&P < 0.05, &&&P < 0.001 vs 7 days; **P < 0.01 vs IL‐1β, #P < 0.05 vs 
Fn‐fs
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F I G U R E  7   Schematic model of IL‐1β‐ and Fn‐fs‐mediated ADAMTS‐12 and ‐7 stimulation by Runx2 and Wnt/β‐catenin signalling 
modulation in OA‐SF. Synovial inflammation and cartilage ECM degradation are key events in OA pathology. SF and other cells in the joint 
produce proinflammatory mediators including IL‐1β. Fn‐fs are released to the microenvironment as consequence of ECM degradation. 
Binding of IL‐1β and Fn‐fs to their receptors, IL‐1 receptor (IL‐1R), and integrins (α, β) and Toll‐like receptors (TLRs), respectively, activates 
MEK‐ERK‐Runx2 axis. This activation converges in the transcription of ADAMTS‐12, with the subsequent degradation of COMP. Inhibition 
of MEK, and consequently ERK, with PD98059 (iERK), decreases Runx2 activation, ADAMTS‐12 transcription and COMP degradation from 
cartilage ECM. IL‐1β and Fn‐fs also activates Wnt/β‐catenin signalling, promoting β‐catenin binding to its nuclear cofactors TCF/LEF (T‐cell 
factor/lymphoid enhancer factor), and inducing ADAMTS‐7 expression, also converging in COMP cleavage from cartilage ECM. Activation 
of Wnt/β‐catenin by IL‐1β is mediated by induction of Wnt7B, which increases its own expression as well. Mechanisms involved in the 
stimulation of this signalling pathway by Fn‐fs are unknown. DKK1 inhibits this signalling pathway by blocking Wnt‐binding to its receptor, 
thus decreasing ADAMTS‐7 transcription and COMP degradation
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with ADAMTS‐7 and ‐12 is largely unexplored. Runx2 is a transcrip‐
tion factor involved in osteoblast differentiation, chondrocytes mat‐
uration and hypertrophy and matrix remodelling. It is up‐regulated in 
chondrocytes during OA,16,35,36 inducing the expression of MMP‐13 
and ADAMTS‐5.9,14,35 In addition, two SNPs of Runx2 gene have 
been suggested as linked to OA.35,37 Different signalling pathways 
are involved in the phosphorylation and activation of ADAMTS‐12.17 
Amongst them, the MAPK especially ERK and p38, have been de‐
scribed as the main implicated in the modulation of Rux2‐mediated 
expression of ADAMTS‐5, and MMP‐13, in response to mechanical 
load or after IL‐1β stimulation with consequences in OA9,18,38,39 Here 
we show that inhibition of ERK signalling decreases IL‐1β or Fn‐fs‐
mediated activation of Runx2 in OA‐SF, and reduces ADAMTS‐12 
expression. These data suggest the involvement of ERK‐Runx2 axis 
in the expression of this ADAMTS in OA‐SF. A previous report also 
demonstrated a fibroblast growth factor 2 (FGF2)‐mediated Runx2 
induction of ADAMTS‐12 in OA cartilage.34
Wnt is a main regulator of joint remodelling, involved in carti‐
lage and bone embryonic development.15,16 Canonical Wnt pathway, 
which includes β‐catenin signalling, has also been widely implicated 
in OA pathogenesis.11,16,22,43,44 DKK1 is an upstream inhibitor of 
Wnt pathway,46 whose expression negatively correlates with OA 
progression.36 Here we report that DKK1 treatment reduces IL‐1β or 
Fn‐fs‐mediated ADAMTS‐7 expression, indicating an essential role 
of Wnt/β‐catenin signalling pathway in ADAMTS‐7 production in SF. 
Then we analysed the expression of two Frizzled receptor ligands 
of the canonical Wnt signalling implicated in the OA pathology. 
Wnt3A is a well‐known ligand, whose involvement in OA has been 
previously described in chondrocytes,15,22,47 Regarding Wnt7B, its 
up‐regulation has been described in OA and RA, with consequences 
in the pathology.43,48 Wnt3A was no detected neither in SF from 
HD, nor in those from OA patients. Nevertheless, we show for the 
first time a higher expression of Wnt7B in OA‐SF compared to those 
from HD. In addition, IL‐1β up‐regulated the expression of Wnt7B, 
corroborating previous studies in chondrocytes,19 while no effects 
were observed after stimulation with Fn‐fs, which could be acting at 
another level along the Wnt/β‐catenin pathway or on other member 
of the Wnt family. Thus, we can conclude that the effect triggered 
by IL‐1β stimulation of Wnt//β‐catenin pathway in OA‐SF would be 
mediated by the induction of Wnt7B, which increases ADAMTS‐7 
levels as well as its own expression in a positive feedback loop. Our 
results in these cells agree with other reports showing IL‐1β up‐reg‐
ulation of Wnt//β‐catenin signalling through down‐regulation of 
Wnt antagonists in human chondrocytes.49 In addition to Wnt7B, 
the involvement of other members of the Wnt family in the OA pa‐
thology has also been described.43,48 Moreover, further study would 
be needed as Runx2 and Wnt signalling mutually regulate their 
expression.35,50,51
COMP as a significant non‐collagenous component of cartilage 
ECM, plays an essential role in matrix assembly by the interaction 
with several ECM proteins.53 Increased levels of COMP and its deg‐
radative fragments have been detected in the serum and synovial 
fluid of OA and RA patients, and have been described as biomarkers 
of joint damage and disease progression.2,26,53,54 Our results indi‐
cate a time‐course degradation of COMP from cartilage explants 
because of the action of OA‐SF, supporting the contribution of 
SF to COMP degradation. Moreover, in cartilage‐SF co‐cultures, 
Wnt//β‐catenin signalling blockade in presence of both, IL‐1β or Fn‐
fs induces a decrease of COMP release, reflecting the increase in 
ADAMTS‐7 expression. Altogether these results point to a greater 
role for ADAMTS‐7 compared to ADAMTS‐12 in the degradation of 
COMP from cartilage ECM, mediated by SF in OA. However, inhibi‐
tion of ERK‐Runx2 axis also reduced Fn‐fs‐mediated COMP degra‐
dation, suggesting the functional implication of ADAMTS‐12, which 
may act late in the course of the disease. All in all, both ADAMTS‐7 
and ‐12 are involved in COMP degradation maintaining OA chro‐
nicity when Fn‐fs are present in the microenvironment. Our results 
are in agreement with previous reports describing that antibodies 
against ADAMTS‐7 and ‐12 additively inhibited COMP degradation 
in OA cartilage explants. Besides, interfering RNA silencing of these 
ADAMTS also prevented COMP degradation in chondrocytes from 
OA patients stimulated with IL‐1β or TNFα.6
The differences observed between OA‐ and HD‐SF should 
be taken into account to specifically target these ADAMTS under 
pathological conditions. While levels of ADAMTS‐7 are physiologi‐
cally higher in OA‐ than in HD‐SF, similar modulation of its expres‐
sion is observed in both. However, although OA‐SF‐mediated COMP 
degradation is inhibited by DKK1 with both stimuli, in HD‐SF this in‐
hibition only occurs in the presence of Fn‐fs. Regarding ADAMTS‐12, 
despite its expression is similar in HD‐ and OA‐SF, when the stimuli 
are present, the blockade of ERK‐RUNX2 signalling and the subse‐
quent COMP inhibition are only observed in OA patients. This spe‐
cific modulation in OA‐SF supports the therapeutic value of these 
catabolic mediators. Collectively our data report for the first time, 
the involvement of ERK‐Runx2 axis and Wnt/β‐catenin signalling in 
the expression of ADAMTS‐12 and ADAMTS‐7 in SF, respectively, 
with the subsequent degradation of COMP from cartilage ECM 
(Figure 7).
Given the loss of cartilage regenerative capacity, the design of 
new therapies based on the blockade of mediators produced by 
neighbouring cells of the joint, such as SF, would help to prevent 
cartilage damage. In this sense, our results might contribute to the 
development of disease‐modifying OA drugs (DMOADs) focusing 
on the ADAMTS as targets for the prevention of ECM components 
degradation. In addition, the potential use of Wnt inhibitors as 
DMOADs is under study.56,57 Nevertheless, given the involvement 
of ADAMTS‐7 and ‐12 in different stages of regeneration and de‐
struction of cartilage and bone, further studies would be needed 
to design therapies based on the fine‐tuning of these signalling 
pathways.
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